OOIR: Observatory of International Research

Papers

(The H4-Index of Thrombosis Research is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Major in-hospital bleeding in patients with pulmonary embolism treated with systemic thrombolysis	90
A novel role of acellular hemoglobin in hemolytic thrombosis	65
Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia	65
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease	65
PO-08: Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms	64
PO-51: Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery	51
PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of superior vena cava syndrome in lung cancer patients	50
Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention	49
Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study	48
DOACs: A perfect fit for patients with bariatric surgery?	48
Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability	42
Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms	41
Is all collagen the same for platelet testing? Editorial on “Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen subs	38
Corrigendum to “Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation” [Thromb. Res. 229 (2023) 53–68]	37
Crosstalk between hemostasis and immunity in cancer pathogenesis	36
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients	36
Investigation of the impact of antithrombin deficiency on the inflammatory response: Results from a single centre cohort study	35
Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors	34
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	34
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice	33
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban	32
Regulation of fibrinogen synthesis	31
Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study	31
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	30
Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination	30

Predicting post-discharge venous thromboembolism and bleeding among medical patients: External validation of a novel risk score utilizing ubiquitous biomarkers	30
Unveiling the predictive capacity of inflammatory and platelet markers for central retinal artery occlusion	28
PO-18: Myocardial infarction and risk of cancer	28